Lobbying Information
Subject Matters
- Economic Development
- Health
- Industry
- Intellectual Property
- International Trade
- Science and Technology
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Ratification and implementation of the intellectual property-related elements of the United States Mexico Canada Agreement.
Policies or Program
- Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with the Canadian Agency for Drugs and Technologies in Health (CADTH) and/or other pan-Canadian health organizations.
- Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
- Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada.
- Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
- The federal role in considering developing and/or funding a national pharmacare program on issues related to access to medicines and rare disease and orphan drug policies
Policies or Program, Regulation
- Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
Regulation
- Amendments to the Patented Medicines Regulations published in Canada Gazette, Part II on August 21, 2019 and June 10, 2020.
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
PO Box 81062
Ottawa, ON K1P 1B1
Canada
Telephone number:
613-800-8340
Client representative
Bob McLay, Chair
Parent Company Information
RAREi - The Canadian Forum for Rare Disease Innovators / iRARE, le Forum canadien des innovateurs spécialisés dans les maladies rares is not a subsidiary of any other parent companies.
Coalition Members Information
- AKCEA Therapeutics, Inc.
-
1220-55 Metcalfe St.
Ottawa, ON K1P 6L5
Canada
- Alexion Pharma Canada Corp.
-
3100 Rutherford Road
Suite 300
Vaughan, ON L4K 0G6
Canada
- Amicus Therapeutics Canada Inc.
-
6500 Trans-Canada Road
4th Floor
Pointe-Claire, QC H9R 0A5
Canada
- Biogen Canada Inc.
-
90 Burnhamthorpe Rd W
Suite 1100
Mississauga, ON L5B 3C3
Canada
- Biomarin Pharmaceuticals Inc.
-
c/o Mark Bennett, Cassels Brock, 40 KING STREET
2100 SCOTIA PLAZA
Toronto, ON M5H 3C2
Canada
- Horizon Therapeutics Canada
-
9131 Keele Street
Unit 4A
Vaughan, ON L4K 0G7
Canada
- Ipsen Pharmaceuticals Canada Inc.
-
5060 Spectrum Way
5th Floor
Mississauga, ON L4W 5N5
Canada
- Mitsubishi Tanabe Pharma Canada
-
100 King St West
Toronto, ON M5X 1C9
Canada
- Recordati Rare Disease Canada Inc.
-
3080 Younge Street
Suite 6060
Toronto, ON M4N 3N1
Canada
- Sanofi-Aventis Canada Inc.
-
2905 Place Louis-R.-Renaud
Laval, QC H7V 0A3
Canada
- Sobi Canada Inc.
-
1155 North Service Rd. West
Unit #11
Oakville, ON L6M 3E3
Canada
- Ultragenyx Canada Inc.
-
2900 - 550 Burrard Street
Vancouver, BC V6C 0A3
Canada
- Vertex Pharmaceuticals (Canada) Inc.
-
20 Bay Street
Suite 1520
Toronto, ON M5J 2N8
Canada
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of RAREi - The Canadian Forum for Rare Disease Innovators / iRARE, le Forum canadien des innovateurs spécialisés dans les maladies rares are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
RAREi - The Canadian Forum for Rare Disease Innovators / iRARE, le Forum canadien des innovateurs spécialisés dans les maladies rares does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
GERALD JEFFCOTT
|
Public offices held
Business address:
458 Clarence Street East, Unit 2
Ottawa, ON K1N 5S1
Canada
Telephone number:
613-851-1602
Consultant Firm and Address
Firm:
3Sixty Public Affairs
Address:
150 Metcalfe Street, Suite 604
Ottawa, ON K2P 1P1
Canada
Telephone number:
613-851-1602
